Safety in psychedelic-assisted therapy: a guide to ketamine and Spravato care

TL;DR:

• In the US today, the only psychedelic-type medicines used in routine clinical care are ketamine and esketamine (Spravato®). Psilocybin and MDMA are still investigational.
• Safety in ketamine and Spravato care rests on screening, monitoring during the session, clear rules for the hours afterward, and a relationship where you can say what you feel.

Safety in therapy sounds straightforward until you look at it closely. Most people assume it means “nothing bad will happen.” But if you are considering ketamine therapy or Spravato®, that assumption can leave you underprepared. Real safety is a set of concrete practices: who is screened and who is not, who is in the room, what is measured during a session, and what happens in the hours afterward. It is also relational. It depends on whether you feel able to speak up, and on how your care team responds when you do. Understanding how it works, not just that it exists, is one of the most useful things you can do before you begin.

Key Takeaways

1. 01

   Know what is approved

   Spravato® is FDA-approved for depression. Ketamine is used off-label. Psilocybin and MDMA are investigational and not available as treatment.

2. 02

   Screening comes first

   A full medical and psychiatric review decides whether treatment is appropriate at all.

3. 03

   Monitoring is built in

   Blood pressure and wellbeing are checked during the session; Spravato® requires at least two hours of observation under its REMS program.

4. 04

   The hours afterward matter

   No driving until the next day, a ride home, and a clear plan for integration.

5. 05

   No guarantee of zero risk

   Honest informed consent and shared responsibility are more realistic than a promise of perfect safety.

What does ‘safety’ mean in modern therapy?

Many of us grew up thinking safety meant the absence of danger. In therapy, that is only part of the picture. Safety is better understood as an active, shared process between you and your care team. It is not established once on an intake form and then left alone. It is built, tested, repaired, and rebuilt as the work goes on.

Part of this is what therapists call co-regulation: in the presence of a calm, attentive clinician, many people find it easier to settle, which makes it possible to approach painful material without being overwhelmed. Holistic therapy pays attention to this kind of embodied safety, alongside symptoms.

A process-level view of safety describes it as something that shifts moment to moment. Therapists watch for the edge of what a person can tolerate and adjust pacing, distance, and emotional intensity to avoid overwhelm and disengagement. In practice, if you are approaching a memory that feels unbearable, a skilled therapist does not push you through. They slow down, check in, and help you find solid ground first.

Here are the core pillars of safety in therapy:

• Physical safety: A secure, private, medically equipped environment, with your health monitored when a medicine is involved
• Emotional safety: Knowing your feelings will be received without judgment or dismissal
• Relational safety: Trust in your clinicians, including their consistency, honesty, and willingness to repair misunderstandings
• Contextual safety: Clarity about what will happen, why, and what your options are at every stage

None of these pillars stands alone. When one weakens, the others are affected too. That is why safety is multidimensional rather than a single checkbox.

What psychedelic-assisted therapy means in practice today

“Psychedelic-assisted therapy” is used loosely online, so it helps to be precise about what is actually available in a US clinic.

• Spravato® (esketamine): a nasal spray, FDA-approved for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behavior. It is approved for depression only, and it can only be given in certified clinics under the REMS program.
• Ketamine: an FDA-approved anesthetic that clinicians prescribe off-label for depression and some other conditions. In ketamine-assisted psychotherapy, a clinician gives the medicine in clinic and a therapist prepares you, stays with you, and helps you integrate the experience afterward.
• Psilocybin and MDMA: investigational. They are being studied in clinical trials but are not FDA-approved treatments. The FDA did not approve MDMA-assisted therapy for PTSD in 2024. Mystic Health does not offer them.

You can read more about the broader field in our guide to psychedelic therapy. The rest of this article focuses on ketamine and Spravato®, because those are the treatments where safety protocols apply to real patients today.

Safety protocols for ketamine and Spravato

Safety in this kind of care is not only about the medicine. It includes psychological preparation, screening for contraindications, monitoring for side effects, and support afterward.

Screening happens before anything is scheduled. A physician reviews your medical history, current medications, psychiatric background, and goals. Some conditions make these medicines inappropriate or call for a careful discussion first: certain blood vessel conditions such as aneurysmal vascular disease, a history of bleeding in the brain, active uncontrolled psychosis or mania, unstable heart disease or uncontrolled high blood pressure, and a known allergy to ketamine or esketamine. A responsible provider tells you plainly if you are not a good candidate.

Monitoring during the session is the part most people ask about. With Spravato®, you give yourself the nasal spray under supervision, your blood pressure is checked before the dose and during the session, and you stay for at least two hours of observation. That window is required by the REMS program and cannot be shortened. With in-clinic ketamine, a clinician gives the medicine and monitors you throughout, and in ketamine-assisted psychotherapy a therapist is present for the whole session.

The hours afterward have their own rules. You cannot drive after either treatment, so you need a ride home. After Spravato®, no driving or operating machinery until you have slept a full night.

Psychological preparation and integration are part of the safety plan, not extras. Before a ketamine session you meet your therapist to talk through what the experience may feel like, what you want from it, and how you will ask for support. Afterward, an integration session helps you make sense of what came up.

The patient consultation workflow typically moves through screening, preparation, the treatment session, and then integration. Each phase carries its own safety considerations.

Common safety challenges and how they are addressed

No honest conversation about this kind of treatment skips the risks. Naming them clearly is part of informed consent.

These effects usually begin during the session and settle before you leave. Less commonly, people feel anxious or vomit. Because ketamine and esketamine can be misused, they are given only under supervision, and your care team will ask about your history with alcohol and other substances. Your physician will review the full list of risks with you before you decide anything.

Research on the investigational psychedelics carries its own cautions. A consensus statement on psilocybin flags distress, anxiety, the emergence of psychotic symptoms, and a possible signal for increased suicidal thinking in a phase II study. Reviews have also found that harm reporting in psilocybin depression research is often incomplete. That is one reason these compounds remain research questions rather than treatments.

Here are five steps responsible clinics take to anticipate and address risk:

1. Screening for contraindications: A thorough medical and psychiatric review before any treatment is scheduled.
2. Clinician-set dosing: Dosing decisions are made by the prescribing clinician, based on your history and how you respond. It is never something to adjust on your own.
3. In-session monitoring: Clinical staff stay present, checking blood pressure and how you are doing.
4. Grounding and support: If a session feels distressing, your therapist or clinician helps you through it with reassurance and simple grounding.
5. Structured follow-up: Integration and follow-up visits are a safety measure, not a bonus. They are also where the team decides whether treatment should continue.

Safety is a shared process: the client’s role and self-advocacy

We feel strongly about this at Mystic Health: you are not a passive recipient of safety. You are an active participant in it. When something shifts during treatment, a good therapist slows down, repairs any rupture in trust, and keeps the work within what you can tolerate without being overwhelmed or shutting down.

Your honesty matters. Telling your team about your current state, your medications, your fears, and your goals gives them what they need to support you well, including the parts that feel uncertain.

Green flags for a safe therapeutic relationship:

• Your clinicians ask regularly how you feel about the pace of treatment
• You feel heard when you raise concerns or discomfort
• Informed consent is revisited, not just signed once
• Integration and follow-up are treated as essential

Red flags that warrant a direct conversation or second opinion:

• Pressure to continue when you have expressed hesitation
• Vague or evasive answers about protocols and risks
• No clear plan for what happens if you feel unwell
• No monitoring, or no one present during the session

Advocating for yourself also means asking questions before you commit. A provider who welcomes your questions is showing you the kind of relational safety good care requires.

The truth most people miss about safety in therapy

Safety cannot be guaranteed. Providers who tell you otherwise are offering you less protection than those who are honest about uncertainty.

Ketamine and Spravato® can help many people whose depression has not responded to other treatment, and the science behind this field is growing. But even when trials show favorable safety profiles, exclusion criteria and monitoring requirements matter, and safety cannot be inferred from effectiveness alone. A treatment working well for many people in a trial does not mean it is right for every person in every context.

As a co-founder, what I care about most is that our clinic treats safety as an ongoing conversation rather than a box ticked at intake. The strongest care relationships are not the ones where nothing difficult happens. They are the ones where difficulty is met honestly, adjusted to thoughtfully, and talked through together.

How Mystic Health approaches safety

We built Mystic Health on the belief that effective treatment and safety strengthen each other.

We provide Spravato® in our REMS-certified clinic in Santa Monica, with at least two hours of monitored rest after each dose. Our ketamine-assisted psychotherapy starts with a medical consultation and screening, includes a preparation session, a monitored session with a licensed therapist present, and an integration session afterward. We also offer psychotherapy and psychiatry for people who want to start without medication or who are not candidates for ketamine. We do not offer psilocybin or MDMA. If you want to talk through whether any of this fits, book a free discovery call.

Frequently asked questions

Recommended

• Patient consultation workflow for psychedelic-assisted therapy
• What is psychedelic therapy? Guide to healing & mental health
• How psychedelics aid healing: science, evidence and insights